Equities analysts predict that Glaukos Corp (NYSE:GKOS) will report $49.44 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Glaukos’ earnings, with estimates ranging from $48.40 million to $50.00 million. Glaukos posted sales of $41.65 million during the same quarter last year, which suggests a positive year-over-year growth rate of 18.7%. The company is scheduled to announce its next earnings report after the market closes on Wednesday, February 27th.
According to Zacks, analysts expect that Glaukos will report full year sales of $176.77 million for the current year, with estimates ranging from $175.60 million to $177.30 million. For the next financial year, analysts anticipate that the firm will report sales of $223.18 million, with estimates ranging from $214.86 million to $233.13 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Glaukos.
Get Glaukos alerts:Separately, Zacks Investment Research cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $58.20.
GKOS stock opened at $68.00 on Tuesday. Glaukos has a 12 month low of $26.75 and a 12 month high of $70.91.
In other news, Director William J. Phd Link sold 41,500 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $57.62, for a total value of $2,391,230.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph E. Gilliam sold 2,100 shares of the stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $58.37, for a total transaction of $122,577.00. Following the completion of the sale, the chief financial officer now directly owns 91,117 shares of the company’s stock, valued at approximately $5,318,499.29. The disclosure for this sale can be found here. In the last three months, insiders sold 48,600 shares of company stock valued at $2,813,957. Corporate insiders own 11.60% of the company’s stock.
Several large investors have recently bought and sold shares of GKOS. Victory Capital Management Inc. purchased a new position in shares of Glaukos during the 4th quarter worth approximately $20,893,000. New York State Common Retirement Fund boosted its position in shares of Glaukos by 139.3% during the 4th quarter. New York State Common Retirement Fund now owns 510,458 shares of the medical instruments supplier’s stock worth $28,672,000 after purchasing an additional 297,158 shares during the period. FMR LLC boosted its position in shares of Glaukos by 16.2% during the 3rd quarter. FMR LLC now owns 1,227,430 shares of the medical instruments supplier’s stock worth $79,660,000 after purchasing an additional 171,268 shares during the period. BlackRock Inc. boosted its position in shares of Glaukos by 6.3% during the 4th quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock worth $144,014,000 after purchasing an additional 151,304 shares during the period. Finally, Baillie Gifford & Co. boosted its position in shares of Glaukos by 11.5% during the 3rd quarter. Baillie Gifford & Co. now owns 1,351,531 shares of the medical instruments supplier’s stock worth $87,714,000 after purchasing an additional 139,868 shares during the period.
About Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Featured Story: Momentum Investing
Get a free copy of the Zacks research report on Glaukos (GKOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment